Author: Investing.com

Home » Archives for Investing.com
Morgan Stanley Announces 11% Dividend Hike and $20B Buyback Following Stress Test
Post

Morgan Stanley Announces 11% Dividend Hike and $20B Buyback Following Stress Test By Investing.com

© Reuters. Morgan Stanley (MS) Announces 11% Dividend Hike and $20B Buyback Following Stress Test By Davit Kirakosyan Following the results of the 2022 stress test, Morgan Stanley (NYSE:) announced it will increase the quarterly dividend on its common stock 11% to $0.775 from the current $0.70 per share. Furthermore, the company’s Board of Directors...

Asian Stocks Up, Following Wall Street Gains
Post

Asian Stocks Up, Following Wall Street Gains By Investing.com

© Reuters. By Zhang Mengying Investing.com – Asia Pacific stocks were up on Monday morning after Wall Street rebounded strongly at the end of last week despite fears of prolonged inflation and a recession caused by monetary tightening.  Japan’s gained 1.40% by 10:37 PM ET (2:37 AM GMT). South Korea’s jumped 2.00%. In Australia, the...

Dow Futures Trade Lower After Positive Week
Post

Dow Futures Trade Lower After Positive Week By Investing.com

© Reuters. By Oliver Gray  Investing.com – U.S. stock futures were trading lower during Sunday’s evening deals, easing from a major rebound last week as investors monitored growing recession fears which were accompanied by a pullback in bond yields, facilitating gains among risk-sensitive sectors. However, despite last week’s bounce, Wall Street is preparing to post...

Cadillac to Price Celestiq EV Around $300,000 - Report
Post

Cadillac to Price Celestiq EV Around $300,000

© Reuters. Cadillac to Price Celestiq EV Around $300,000 – Report By Michael Elkins General Motors (NYSE:) is set to reveal later this summer a prototype of the car, named the Celestiq. The Celestiq electric sedan will be made under GM’s luxury brand, Cadillac, and will be priced at around $300,000, according to the Wall...

U.S. FDA lifts clinical hold on Inovio's COVID-19 vaccine trial
Post

Sarepta Therapeutics Shares Down 3% on FDA’s Clinical Hold on SRP-5051 By Investing.com

Sarepta Therapeutics (SRPT) Shares Down 3% on FDA’s Clinical Hold on SRP-5051 By Davit Kirakosyan Sarepta Therapeutics, Inc. (NASDAQ:) shares were trading more than 3% lower after-hours following the company’s announcement, according to which the U.S. Food and Drug Administration (FDA) placed a clinical hold on SRP-5051 (vesleteplirsen) for the treatment of Duchenne muscular dystrophy....